Page last updated: 2024-11-10

arachidonic acid omega-9 hydroperoxide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

12-HPETE: RN given refers to cpd without isomeric designation; 12-HPETE may be used inconsistently in literature as synonym for cpds with various tetraene-locants; caused dose-dependent constriction of cat coronary arteries [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

12(S)-HPETE : The (S)-enantiomer of 12-HPETE. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5280892
CHEMBL ID1447811
CHEBI ID15626
SCHEMBL ID904542
MeSH IDM0075766

Synonyms (49)

Synonym
omega-9-hydroperoxyarachidonic acid
12-oohete
omega-9 hpaa
12-hpete
(5z,8z,10e,12s,14z)-12-hydroperoxyicosa-5,8,10,14-tetraenoic acid
CHEBI:15626 ,
12s-hpete
LMFA03060013
12s-hydroperoxy-5z,8z,10e,14z-eicosatetraenoic acid
IDI1_033791
(5z,8z,10e,14z)-(12s)-12-hydroperoxyicosa-5,8,10,14-tetraenoic acid
(5z,8z,10e,14z)-(12s)-12-hydroperoxyicosa-5,8,10,14-tetraenoate
12(s)-hpete
12-hydroperoxyeicosatetraenoic acid
12-hydroperoxyeicosatetraenoate
12-hydroperoxyicosatetraenoate
12-hydroperoxyicosatetraenoic acid
C05965
BSPBIO_001321
NCGC00161250-01
NCGC00161250-02
NCGC00161250-03
12-(s)-hydroperoxyeicosatetraenoic acid
12-(s)-hpete
gtpl2481
HMS1989C03
BML1-C05
HMS1361C03
HMS1791C03
71774-10-2
5,8,10,14-eicosatetraenoicacid, 12-hydroperoxy-, (5z,8z,10e,12s,14z)-
SCHEMBL904542
CHEMBL1447811
12-hydroperoxyarachidonic acid, (s)-
5,8,10,14-eicosatetraenoic acid, 12-hydroperoxy-, (5z,8z,10e,12s,14z)-)-
12-hpete, (s)-
(5z,8z,10e,12s,14z)-12-hydroperoxy-5,8,10,14-eicosatetraenoic acid
54G1W9LPV0 ,
12(s)-hydroperoxy-5z,8z,10e,14z-eicosatetraenoic acid
HMS3402C03
unii-54g1w9lpv0
12-hydroxy-5,8,10,14 eicosatetraenoic acid
(s)-12-hpete
Q27070764
SR-01000946956-1
sr-01000946956
12(s)-hpete lipid maps(r) ms standard
PD018246
AKOS040756145

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Dose-response studies indicated that 5-HPETE was a potent (IC25 = 10(-8) M) inhibitor of Na+, K(+)-ATPase activity."( 5-HPETE is a potent inhibitor of neuronal Na+, K(+)-ATPase activity.
Foley, TD, 1997
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
HPETEMono-hydroperoxy (e)icosatetraenoic acids (HPETEs) are the primary products of lipoxygenase-catalysed oxygenation of arachidonic acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (50)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of lipids500463
Fatty acid metabolism113203
Arachidonic acid metabolism3682
Synthesis of 12-eicosatetraenoic acid derivatives412
Arachidonic Acid Metabolism2966
Leukotriene C4 Synthesis Deficiency2966
Piroxicam Action Pathway2967
Acetylsalicylic Acid Action Pathway2967
Etodolac Action Pathway2967
Ketoprofen Action Pathway2967
Ibuprofen Action Pathway5076
Rofecoxib Action Pathway2967
Diclofenac Action Pathway2967
Sulindac Action Pathway2967
Celecoxib Action Pathway3573
Ketorolac Action Pathway2967
Suprofen Action Pathway2967
Bromfenac Action Pathway2967
Indomethacin Action Pathway3067
Mefenamic Acid Action Pathway2967
Oxaprozin Action Pathway2967
Nabumetone Action Pathway2967
Naproxen Action Pathway2967
Diflunisal Action Pathway2967
Meloxicam Action Pathway2967
Valdecoxib Action Pathway2967
Antipyrine Action Pathway2967
Antrafenine Action Pathway2967
Carprofen Action Pathway2967
Etoricoxib Action Pathway2967
Fenoprofen Action Pathway2967
Flurbiprofen Action Pathway2967
Magnesium Salicylate Action Pathway2967
Lumiracoxib Action Pathway2967
Lornoxicam Action Pathway2967
Phenylbutazone Action Pathway2967
Nepafenac Action Pathway2967
Trisalicylate-Choline Action Pathway2967
Tolmetin Action Pathway2967
Tiaprofenic Acid Action Pathway2967
Tenoxicam Action Pathway2967
Salsalate Action Pathway2967
Salicylate-Sodium Action Pathway2967
Salicylic Acid Action Pathway2967
Acetaminophen Action Pathway2967
Prostaglandin and Leukotriene metabolism ( Prostaglandin and Leukotriene metabolism )2223
Eicosanoid metabolism via lipooxygenases (LOX)040
Arachidonic acid (AA, ARA) oxylipin metabolism076
Eicosanoid metabolism via lipoxygenases (LOX)040
Eicosanoid synthesis026

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency39.81070.003245.467312,589.2998AID2517
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1346643Rat TRPV1 (Transient Receptor Potential channels)2000Proceedings of the National Academy of Sciences of the United States of America, May-23, Volume: 97, Issue:11
Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (149)

TimeframeStudies, This Drug (%)All Drugs %
pre-199053 (35.57)18.7374
1990's51 (34.23)18.2507
2000's33 (22.15)29.6817
2010's10 (6.71)24.3611
2020's2 (1.34)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.24

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.24 (24.57)
Research Supply Index5.03 (2.92)
Research Growth Index4.27 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.24)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews10 (6.58%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other142 (93.42%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]